^
BIOMARKER:
HER-2 S310F
i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
Related biomarkers:
›
HER-2 S310F
|
Breast Cancer
|
HER-2 S310F
|
Breast Cancer
|
trastuzumab + everolimus Sensitive: C3 – Early Trials
Transl Oncol - 3 weeks (NewC3)
|
trastuzumab + everolimus Sensitive: C3 – Early Trials
Transl Oncol - 3 weeks - (New C3)
|
HER-2 S310F
|
Solid Tumor
|
HER-2 S310F
|
Solid Tumor
|
BDTX-189 Sensitive: C2 – Inclusion Criteria
|
BDTX-189 Sensitive: C2 – Inclusion Criteria
|
HER-2 S310F
|
LUAD
|
HER-2 S310F
|
LUAD
|
afatinib Sensitive: C4 – Case Studies
|
afatinib Sensitive: C4 – Case Studies
|
HER-2 S310F
|
CRC
|
HER-2 S310F
|
CRC
|
afatinib Sensitive: C4 – Case Studies
|
afatinib Sensitive: C4 – Case Studies
|
HER-2 S310F
|
HER2 Negative Breast Cancer
|
HER-2 S310F
|
HER2 Negative Breast Cancer
|
lapatinib Sensitive: C4 – Case Studies
|
lapatinib Sensitive: C4 – Case Studies
|
HER-2 S310F
|
Gallbladder Cancer
|
HER-2 S310F
|
Gallbladder Cancer
|
lapatinib Sensitive: C4 – Case Studies
|
lapatinib Sensitive: C4 – Case Studies
|
HER-2 S310F
|
NSCLC
|
HER-2 S310F
|
NSCLC
|
ado-trastuzumab emtansine Sensitive: D – Preclinical
|
ado-trastuzumab emtansine Sensitive: D – Preclinical
|
HER-2 S310F
|
CRC
|
HER-2 S310F
|
CRC
|
cetuximab Resistant: D – Preclinical
|
cetuximab Resistant: D – Preclinical
|
HER-2 S310F
|
CRC
|
HER-2 S310F
|
CRC
|
panitumumab Resistant: D – Preclinical
|
panitumumab Resistant: D – Preclinical
|
